1.Baseline indexes
|
Join Date | 2014-11-13 |
1.1.Inclusion Criteria
|
Age 20-70 years old | Yes
|
|
Patient of CAG | Yes
|
1.2.Exclusion Criteria
|
Diagnosed or unable to rule out at least one of the following diseases： | |
|
At least one drug as listed were taken two weeks before this trial: | |
|
With at least one of the serious comorbidities as listed: | |
|
Female patients pregnant or lactating | |
|
Dropping out of this trials before the end of treatment, or can't cooperate with researchers |
1.3.Treatment
|
Group | 6-month treatment of Weierkang
|
2.Before the treatment
|
Date before treatment |
|
2.1.Symptoms
|
epigastric pain | |
|
poor appetite | |
|
Regurgitation | |
|
Abdominal distension | |
|
Belching | |
|
Nausea | |
|
Emesis |
2.2.pathologic diagnosis
|
Inflammation | |
|
Atrophy | |
|
Intestinal metaplasia |
3.After the treatment
|
Date after treatment | 2015-06-22 |
3.1.Symptoms
|
epigastric pain | None
|
|
oor appetite | None
|
|
Regurgitation | None
|
|
Abdominal distension | None
|
|
Belching | None
|
|
Nausea | None
|
|
Emesis | None
|
3.2.pathologic diagnosis
|
Inflammation | Mild
|
|
Atrophy | None
|
|
Intestinal metaplasia | Moderate
|